• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
African League Against Rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic.非洲抗风湿病联盟(AFLAR)关于 COVID-19 大流行期间风湿病管理的初步建议。
Clin Rheumatol. 2021 Sep;40(9):3445-3454. doi: 10.1007/s10067-020-05355-2. Epub 2020 Sep 2.
2
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.美国风湿病学会在 COVID-19 大流行期间成人患者风湿性疾病管理指南:第 1 版。
Arthritis Rheumatol. 2020 Aug;72(8):1241-1251. doi: 10.1002/art.41301. Epub 2020 Jun 5.
3
American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2.美国风湿病学会关于 COVID-19 大流行期间儿童风湿病管理的指南:第 2 版。
Arthritis Rheumatol. 2021 Aug;73(8):e46-e59. doi: 10.1002/art.41772. Epub 2021 Jun 10.
4
American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1.美国风湿病学会关于 COVID-19 大流行期间儿童风湿病管理的指南:第 1 版。
Arthritis Rheumatol. 2020 Nov;72(11):1809-1819. doi: 10.1002/art.41455. Epub 2020 Sep 28.
5
Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020.管理 COVID-19 大流行期间的风湿性疾病患者:法国风湿病学会回答了截至 2020 年 5 月最常被问到的问题。
Joint Bone Spine. 2020 Oct;87(5):431-437. doi: 10.1016/j.jbspin.2020.05.006. Epub 2020 May 27.
6
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2.美国风湿病学会在 COVID-19 大流行期间成人风湿性疾病管理指南:第 2 版。
Arthritis Rheumatol. 2020 Sep;72(9):e1-e12. doi: 10.1002/art.41437. Epub 2020 Jul 30.
7
Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic.亚太风湿病学会联盟关于 COVID-19 大流行期间风湿病患者管理的共识更新声明。
Int J Rheum Dis. 2021 Jun;24(6):733-745. doi: 10.1111/1756-185X.14124. Epub 2021 May 4.
8
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3.美国风湿病学会在 COVID-19 大流行期间成人患者风湿病管理指南:第 3 版。
Arthritis Rheumatol. 2021 Feb;73(2):e1-e12. doi: 10.1002/art.41596. Epub 2020 Dec 5.
9
The impact of COVID-19 on rheumatology practice across Africa.COVID-19 对非洲风湿病学实践的影响。
Rheumatology (Oxford). 2021 Jan 5;60(1):392-398. doi: 10.1093/rheumatology/keaa600.
10
Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries.COVID-19 大流行对炎症性风湿和肌肉骨骼疾病患者管理决策的影响:一项在 EULAR 国家开展的调查。
Ann Rheum Dis. 2021 Apr;80(4):518-526. doi: 10.1136/annrheumdis-2020-218697. Epub 2020 Nov 6.

引用本文的文献

1
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic.临床实践新进展:COVID-19 大流行期间炎症性肠病的管理。
Gut. 2022 Jul;71(7):1426-1439. doi: 10.1136/gutjnl-2021-326784. Epub 2022 Apr 27.
2
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.皮下注射英夫利昔单抗治疗风湿性疾病和炎症性肠病的观点:COVID-19 时代之前、期间和之后。
Adv Ther. 2022 Jun;39(6):2342-2364. doi: 10.1007/s12325-021-01990-6. Epub 2022 Jan 6.
3
Long COVID: rheumatologic/musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6 months.长新冠:COVID-19 住院幸存者在 3 个月和 6 个月时的风湿免疫/肌肉骨骼症状。
Clin Rheumatol. 2022 Jan;41(1):289-296. doi: 10.1007/s10067-021-05942-x. Epub 2021 Oct 29.
4
Rheumatic diseases in Africa.非洲的风湿性疾病。
Nat Rev Rheumatol. 2021 Jun;17(6):363-374. doi: 10.1038/s41584-021-00603-4. Epub 2021 Apr 13.
5
Impact of COVID-19 pandemic on management of autoimmune and inflammatory diseases in Morocco.新冠疫情对摩洛哥自身免疫性和炎性疾病管理的影响。
Pan Afr Med J. 2020 Nov 16;37:240. doi: 10.11604/pamj.2020.37.240.26188. eCollection 2020.
6
Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends.新冠疫情时代民众对抗风湿药物的关注度:来自谷歌趋势的见解
Clin Rheumatol. 2021 May;40(5):2047-2055. doi: 10.1007/s10067-020-05490-w. Epub 2020 Oct 31.
7
COVID-19 and African rheumatology: progress in adversity.2019冠状病毒病与非洲风湿病学:逆境中的进展
Lancet Rheumatol. 2020 Dec;2(12):e732-e734. doi: 10.1016/S2665-9913(20)30347-7. Epub 2020 Sep 30.
8
Effectiveness of reproductive health counseling of women with systemic lupus erythematosus: observational cross-sectional study at an academic lupus clinic.系统性红斑狼疮女性生殖健康咨询的有效性:在一家学术性狼疮诊所进行的观察性横断面研究。
Rheumatol Int. 2021 Feb;41(2):403-408. doi: 10.1007/s00296-020-04671-9. Epub 2020 Aug 7.

本文引用的文献

1
Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.2019冠状病毒病(COVID-19)与心血管疾病:关于血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的发病和严重程度潜在影响的观点
J Am Heart Assoc. 2020 Apr 7;9(7):e016219. doi: 10.1161/JAHA.120.016219. Epub 2020 Apr 1.

非洲抗风湿病联盟(AFLAR)关于 COVID-19 大流行期间风湿病管理的初步建议。

African League Against Rheumatism (AFLAR) preliminary recommendations on the management of rheumatic diseases during the COVID-19 pandemic.

机构信息

Rheumatology Department, Dumfries and Galloway Royal Infirmary, Cargenbridge, Dumfries, UK.

School of Health and Life Sciences, Glasgow Caledonian University, Cowcaddens Road, Glasgow,, G4 0BA, UK.

出版信息

Clin Rheumatol. 2021 Sep;40(9):3445-3454. doi: 10.1007/s10067-020-05355-2. Epub 2020 Sep 2.

DOI:
10.1007/s10067-020-05355-2
PMID:32876786
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7465880/
Abstract

OBJECTIVES

To develop recommendations for the management of rheumatic and musculoskeletal diseases (RMDs) during the COVID-19 pandemic.

METHOD

A task force comprising of 25 rheumatologists from the 5 regions of the continent was formed and operated through a hub-and-spoke model with a central working committee (CWC) and 4 subgroups. The subgroups championed separate scopes of the clinical questions and formulated preliminary statements of recommendations which were processed centrally in the CWC. The CWC and each subgroup met by several virtual meetings, and two rounds of voting were conducted on the drafted statements of recommendations. Votes were online-delivered and recommendations were pruned down according to predefined criteria. Each statement was rated between 1 and 9 with 1-3, 4-6 and 7-9 representing disagreement, uncertainty and agreement, respectively. The levels of agreement on the statements were stratified as low, moderate or high according to the spread of votes. A statement was retired if it had a mean vote below 7 or a 'low' level of agreement.

RESULTS

A total of 126 initial statements of recommendations were drafted, and these were reduced to 22 after the two rounds of voting.

CONCLUSIONS

The preliminary statements of recommendations will serve to guide the clinical practice of rheumatology across Africa amidst the changing practices and uncertainties in the current era of COVID-19. It is recognized that further updates to the recommendations will be needed as more evidence emerges. Key Points • AFLAR has developed preliminary recommendations for the management of RMDs in the face of the COVID-19 pandemic. • COVID-19 is an unprecedented experience which has brought new concerns regarding the use of some disease-modifying anti-rheumatic drugs (DMARDs), and these recommendations seek to provide guidelines to the African rheumatologists. • Hydroxychloroquine shortage has become rampart across Africa as the drug is being used as prophylaxis against COVID-19 and this may necessitate a review of treatment plan for some patients with RMDs. • Breastfeeding should continue for as long as possible if a woman is positive for SARS-CoV-2 as there is currently no evidence that the infection can be transmitted through breast milk.

摘要

目的

制定在 COVID-19 大流行期间管理风湿和肌肉骨骼疾病(RMD)的建议。

方法

成立了一个由来自大陆 5 个地区的 25 名风湿病专家组成的工作组,通过中央工作组(CWC)和 4 个分组的中心辐射型模式运作。分组分别负责不同临床问题的范围,并制定初步建议声明,这些声明在 CWC 进行集中处理。CWC 和每个分组都通过多次虚拟会议进行了会议,并对建议草案进行了两轮投票。投票是在线进行的,建议根据预定义的标准进行修剪。每个声明的评分范围为 1 到 9 分,1-3 分、4-6 分和 7-9 分分别表示不同意、不确定和同意。根据投票的分布情况,将声明的一致性分为低、中和高三个层次。如果平均投票低于 7 分或一致性为“低”,则该声明将被退休。

结果

共起草了 126 项初步建议声明,经过两轮投票后,这些声明减少到 22 项。

结论

在当前 COVID-19 时代,随着实践和不确定性的不断变化,这些初步建议声明将有助于指导非洲的风湿病临床实践。认识到随着更多证据的出现,需要对建议进行进一步更新。关键点:

  • AFLAR 在面对 COVID-19 大流行时制定了 RMD 管理的初步建议。

  • COVID-19 是一次前所未有的经历,它引起了人们对某些疾病修饰抗风湿药物(DMARDs)使用的新关注,这些建议旨在为非洲风湿病学家提供指导。

  • 羟氯喹在非洲各地短缺,因为该药物被用作 COVID-19 的预防药物,这可能需要重新审查一些 RMD 患者的治疗计划。

  • 如果妇女对 SARS-CoV-2 呈阳性,应尽可能长时间地继续母乳喂养,因为目前没有证据表明感染可以通过母乳传播。